Skip to product information
1 of 1

BDCA2/DLEC4C Fc Chimera Protein, Human

BDCA2/DLEC4C Fc Chimera Protein, Human

Catalog Number: UA011101 Reactivity: Human Conjugation: Unconjugated Brand: UA BIOSCIENCE
Price:
Regular price $256 USD
Regular price Sale price $256 USD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Human
Synonyms BDCA2; BDCA-2; BDCA2MGC125791; blood dendritic cell antigen 2 protein; Blood dendritic cell antigen 2; CD303 antigen; CD303; CLEC4C; CLECSF11; CLECSF11PRO34150; CLECSF7; C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamilymember 11; C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamilymember 7; C-type lectin domain family 4 member C; C-type lectin superfamily member 7; dendritic cell lectin b; Dendritic lectin; DLEC; DLECMGC125792; HECL; HECLMGC125793; MGC125789; PRO34150
Accession Q8WTT0
Amino Acid Sequence

Asn45-Ile213 with Human IgG1 Fc Tag at N-Terminus

Expression System HEK293
Molecular Weight

50-60kDa (Reducing)

Purity >95% by SDS-PAGE
Endotoxin <0.1EU/μg
Conjugation Unconjugated
Tag Human IgG1 Fc
Physical Appearance Lyophilized Powder
Storage Buffer PBS, PH7.4, 5% trehalose
Reconstitution

Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

Stability & Storage

· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.

· 3 months, -20 to -80℃ under sterile conditions after reconstitution.

· 1 week, 2 to 8℃ under sterile conditions after reconstitution.

· Please avoid repeated freeze-thaw cycles.

Reference

Wu P, et al. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients. Clin Immunol. 2008,
Lim SM, et al. CLEC4C p.K210del variant causes impaired cell surface transport in plasmacytoid dendritic cells of amyotrophic lateral sclerosis. Oncotarget. 2016
Robak E, Braun M, Robak T. Leukemia Cutis-The Current View on Pathogenesis, Diagnosis, and Treatment. Cancers (Basel). 2023,
Wilson NR, et al. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma. 2022,
5. Riboldi E, et al. Human C-type lectin domain family 4, member C (CLEC4C/BDCA-2/CD303) is a receptor for asialo-galactosyl-oligosaccharides. J Biol Chem. 2011

Background

Dendritic Cell Lectin (DLEC), also known as BDCA-2, CD303, HECL, and alternatively designated as CLEC4C/CLECSF11/CLECSF7, is a 38 kDa type II transmembrane protein belonging to the C-type lectin family. The expression of DLEC is primarily restricted to plasmacytoid dendritic cells (pDCs) and is downregulated as these cells mature.
pDCs are integral to the innate immune response, particularly in the production of IFN-alpha/beta upon exposure to Toll-like receptor (TLR) 7 and TLR9 agonists, such as microbial CpG DNA. The ligation of DLEC on pDCs with specific antibodies has been shown to attenuate the CpG-stimulated production of interferons and to bias the response towards a Th1 phenotype.
Monoclonal antibodies targeting CLEC4C have demonstrated disease control in patients with cutaneous lupus erythematosus. The modulation of IFN-alpha production mediated by CLEC4C is regulated through the masking and unmasking of galactose moieties on the lectin. This mechanism represents a novel potential strategy for modulating immune responses in various pathological conditions.

Picture

SDS-PAGE

1μg (R: reducing condition, N: non-reducing condition).

ELISA

Immobilized Purified anti-human CD303 (BDCA-2) Antibody at 2.0μg/mL (100μL/well) can bind BDCA2/DLEC4C Fc Chimera Protein, Human (Cat. No. UA011101) with EC50 of 0.81-1.40 ng/mL. 

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)